Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNEUROPHARMACOLOGY

S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: I. Interaction with Cloned Human (h)5-HT1A, Dopamine hD2/hD3 and hα2A-Adrenergic Receptors in Relation to Modulation of Cortical Monoamine Release and Activity in Models of Potential Antidepressant Activity

Mark J. Millan, Adrian Newman-Tancredi, Jean-Michel Rivet, Mauricette Brocco, Pierre Lacroix, Valérie Audinot, Laetitia Cistarelli and Alain Gobert
Journal of Pharmacology and Experimental Therapeutics July 1997, 282 (1) 132-147;
Mark J. Millan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian Newman-Tancredi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Michel Rivet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauricette Brocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Lacroix
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valérie Audinot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laetitia Cistarelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Gobert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The novel, potential anxiolytic, S 15535 (4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine), is an agonist and antagonist (weak partial agonist) at pre- and postsynaptic serotonin (5-HT)1A receptors, respectively. Herein, we characterized its influence on dialysate levels of 5-HT, dopamine (DA) and NAD simultaneously determined in single samples of the frontal cortex (FCX) of freely moving rats, and compared its activity in several other models of potential antidepressant (AD) properties with those of the 5-HT reuptake inhibitor (SSRI), fluoxetine. S 15535 displayed high affinity at cloned human (h) 5-HT1Areceptors (K i = 0.7 nM) and >250-fold lower affinity at cloned hD2 (400 nM), hD3 (248 nM) and hα2A-adrenergic (AR) (190 nM) receptors. S 15535 (0.08–5.0 mg/kg s.c.) markedly and dose-dependently suppressed dialysate levels of 5-HT in the FCX, nucleus accumbens and striatum of freely moving rats, whereas fluoxetine (10.0 mg/kg s.c.) elevated levels of 5-HT in each structure. In contrast to 5-HT, dialysate levels of DA and NAD in the FCX were dose-dependently increased by S 15535, and this effect was mimicked by fluoxetine. The influence of S 15535 and fluoxetine on FCX levels of DA was regionally specific inasmuch as dialysate levels of DA in the accumbens and striatum were not modified. The selective 5-HT1A antagonist, WAY 100,635 (N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl) cyclohexanecarboxamide (0.16) transiently elicited a slight increase in cortical levels of 5-HT, an action opposite to that of S 15535. Further, in the presence of WAY 100,635 (0.16), the influence of S 15535 (0.63) on cortical levels of 5-HT, DA and NAD was markedly attenuated. Upon chronic administration of S 15535 or fluoxetine (10.0 mg/kg s.c. daily for 14 days, in each case), there was no significant alteration in the density of β-AR receptors in the FCX. However, in contrast to fluoxetine, S 15535 elicited a significant (25%) decrease in the density (B max) of 5-HT2Areceptors labeled by [3H]ketanserin in the cortex; there was no alteration in K d. In a learned helplessness paradigm in rats, S 15535 (0.63–40.0 mg/kg p.o.) markedly reduced escape deficits on each of three consecutive days of testing. Fluoxetine (2.0–8.0 mg/kg i.p.) was also active in each session, but presented a biphasic dose-response curve. Finally, under the conditions used, neither S 15535 (0.63–10.0) nor fluoxetine (0.63–10.0) decreased immobility time in the forced swim test. In conclusion, S 15535 is a selective ligand of cloned, h5-HT1A receptors. Its agonist actions at 5-HT1A autoreceptors underlie its ability to decrease extracellular levels of 5-HT in the FCX, and likely contribute to the increase in extracellular levels of DA and NAD evoked by S 15535 in this structure. Further, S 15535 is active in several other, although not all, models of potential AD activity. Thus, although S 15535 is under development as an anxiolytic agent, a further characterization of its putative AD actions would be of interest.

Footnotes

  • Send reprint requests to: Dr Mark J. Millan, Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, 125, Chemin de Ronde, 78290 - Croissy-sur-Seine (Paris, France).

  • Abbreviations:
    AD
    antidepressant
    AR
    adrenergic
    CHO
    Chinese hamster ovary
    DA
    dopamine
    LH
    learned helplessness
    NAD
    noradrenaline
    5-HT
    serotonin
    SSRI
    serotonin reuptake inhibitor
    5-HIAA
    5-hydroxyindole acetic acid
    DOPAC
    dihydroxyphenylacetic acid
    DRN
    dorsal raphe nucleus
    • Received March 19, 1996.
    • Accepted December 4, 1996.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 1
1 Jul 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: I. Interaction with Cloned Human (h)5-HT1A, Dopamine hD2/hD3 and hα2A-Adrenergic Receptors in Relation to Modulation of Cortical Monoamine Release and Activity in Models of Pot…
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNEUROPHARMACOLOGY

S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: I. Interaction with Cloned Human (h)5-HT1A, Dopamine hD2/hD3 and hα2A-Adrenergic Receptors in Relation to Modulation of Cortical Monoamine Release and Activity in Models of Potential Antidepressant Activity

Mark J. Millan, Adrian Newman-Tancredi, Jean-Michel Rivet, Mauricette Brocco, Pierre Lacroix, Valérie Audinot, Laetitia Cistarelli and Alain Gobert
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 132-147;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherNEUROPHARMACOLOGY

S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: I. Interaction with Cloned Human (h)5-HT1A, Dopamine hD2/hD3 and hα2A-Adrenergic Receptors in Relation to Modulation of Cortical Monoamine Release and Activity in Models of Potential Antidepressant Activity

Mark J. Millan, Adrian Newman-Tancredi, Jean-Michel Rivet, Mauricette Brocco, Pierre Lacroix, Valérie Audinot, Laetitia Cistarelli and Alain Gobert
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 132-147;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glycine receptor modulation using monoclonal antibodies
  • Iclepertin (BI 425809) in Schizophrenia-Related Models
  • D1 Agonist Versus Methylphenidate on PFC Working Memory
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics